DAS181 in Patients With Parainfluenza

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID) (NIH)

Overall Status

Withdrawn

CT.gov ID

NCT01441024

Collaborator

(none)

Enrollment

Arms

35.5

Duration (Months)

Study Details

Study Description

Brief Summary

Background:

Parainfluenza is a virus that can cause infections in people. Most people infected with this virus have mild symptoms including fever, cough, red eyes, or runny nose (a common cold). Some people, especially those with a weakened immune system, get very sick from this virus. They may have difficulty breathing or develop lung infections. Currently, there are no specific treatments for parainfluenza. However, a drug called DAS181 may make the virus go away faster. Researchers are interested in testing DAS181 to see if it is safe and effective against parainfluenza.

Objectives:

To test the safety and effectiveness of DAS181 as a treatment for parainfluenza.

Eligibility:

Individuals at least 18 years of age who have the parainfluenza virus and have developed symptoms within the past 10 days.

Design:

Participants will be screened with a physical exam, medical history, and questions about symptoms and activity levels. Participants will also have a lung function test and provide blood and nasal fluid samples.
DAS181 is an inhaled medication, and everyone will receive a study medication inhaler. Participants will receive either DAS181 or a placebo through the inhaler. They will take it once every day for 5 days.
Participants will have monitoring visits on days 2, 4, 7, 10, 14, and 28 to provide blood and nasal fluid samples and have a lung function test.
Participants who still have the virus in their system on Day 28 will return to the clinic on Day 42 for more tests. Participants who still have the virus in their system on Day 42 will return to the clinic on Day 56 for more tests.
Participants will have followup visits 6 months and 1 year after the start of the study.

Condition or Disease	Intervention/Treatment	Phase
Parainfluenza Infection	Drug: DAS181 Other: Placebo	Phase 2

Detailed Description

Parainfluenza virus (PIV) infections cause considerable morbidity in the immunocompromised population. In the immunocompetent population, PIV is usually self-limited, but can cause more severe disease including pneumonia and tracheobronchitis in adults, and croup and bronchiolitis in young children. DAS181, an inhaled sialidase, cleaves the binding site of PIV from respiratory mucosal cells limiting the ability of PIV to infect new cells. This may improve outcomes in patients with PIV infections.

This exploratory randomized double-blind Phase 2 study will assess the safety and tolerability, and explore the efficacy of DAS181 versus placebo for the treatment of parainfluenza. Thirty eligible patients diagnosed with parainfluenza will be randomized in a 2:1 allocation to receive either DAS181-F02 formulation (10 mg times 5 days) or placebo. Subjects will be followed on Study Days 0, 2, 4, 7, 10, 14, 28, 180, and 365 with a series of clinical, pulmonary function, functional status, virologic, and safety assessments.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Primary Purpose:

Treatment

Official Title:

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of DAS181 in Patients With Parainfluenza Infection

Study Start Date :

Jul 14, 2011

Actual Primary Completion Date :

Feb 27, 2014

Actual Study Completion Date :

Jun 30, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1 DAS181	Drug: DAS181 20 mg per day of DAS181-FO3 for 5 days
Placebo Comparator: 2 Placebo	Other: Placebo 20 mg per day of Lactose for 5 days

Arm

Intervention/Treatment

Experimental: 1

DAS181

Drug: DAS181

20 mg per day of DAS181-FO3 for 5 days

Placebo Comparator: 2

Placebo

Other: Placebo

20 mg per day of Lactose for 5 days

Outcome Measures

Primary Outcome Measures

Number patients with at least 1 grade 3/4/SAE that are possibly, probably, or definitely related to the study product by Study Day 28. [study day 28]

Secondary Outcome Measures

Virologic Endpoints: Viral shedding by qualitative PCR or culture. [1 year]
Clinical Endpoints: Clinical symptoms, Fever, Radiographic evidence of lower tract disease by CT (if obtained clinically), Death, Hospitalization, Use of supplemental oxygen. [1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 99 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

INCLUSION CRITERIA:

Age greater than or equal to 18 years
Positive culture, DFA, PCR or other clinical assay for parainfluenza
Symptomatic upper or lower respiratory tract disease (e.g., pharyngitis, cough, tracheobronchitis, bronchiolitis, pneumonia). Fever alone is not sufficient.
Onset of illness within the last 10 days
Females who are able to become pregnant (i.e., are not postmenopausal, have not undergone surgical sterilization, and are sexually active with men) must agree to use at least 2 effective forms of contraception from the date of informed consent through Study Day 28 of the study. At least 1 of the methods of contraception should be a barrier method
Willingness to have samples stored

EXCLUSION CRITERIA:

Known hypersensitivity to DAS181 or any of its components
Women who are pregnant (positive serum or urine pregnancy test), who are attempting to become pregnant, or who are breast-feeding
Mechanical ventilation, acute respiratory distress, or otherwise unable to tolerate the drug delivery device (Cyclohaler)
Allergy or history of allergy to milk or lactose
Previous or current history of asthma or chronic obstructive pulmonary disease (COPD) requiring daily medication
Any significant findings in the patient s medical history or physical examination that, in the opinion of the investigator, would affect patient safety or compliance with the dosing schedule